Dr Thomas Newsom-Davis is a Consultant Medical Oncologist based at The Chelsea and Westminster Hospital NHS Foundation Trust.
Dr Newsom-Davis trained at University College and Middlesex School of Medicine, and graduated in anatomy and medicine in 1998. He subsequently specialised in medical oncology at Charing Cross and Hammersmith Hospitals. During this time he completed a PhD in tumour immunology, funded by Cancer Research UK, and went on to become a Clinical Lecturer in medical oncology at Imperial College London, supported by the Wellcome Trust and Academy of Medical Sciences. He has published several peer-reviewed papers and presented at many conferences.
Dr Newsom-Davis specialises in the treatment of lung cancer, mesothelioma and other thoracic malignancies. Dr Newsom-Davis has taught widely at both under-gradate and post-graduate levels, as well as being an invited lecturer for various organisations including the Royal College of Physicians and the British Medical Journal. He foundered the first Royal Society of Medicine/LCA acute oncology course, and also runs regular simulation based acute oncology training courses at Chelsea and Westminster. His work was recognised in the 2011 Health Services Journal Awards.
Awards Dr Newsom-Davis has received include: 2011 Health Services Journal Awards, Clinical Service Redesign (short listed), 2006 McElwain Scholarship, Association of Cancer Physicians, and in 2006 President’s Prize, Royal College of Physicians.
He is a member of the Royal College of Physicians, Association of Cancer Physicians, European Society of Medical Oncology, British Thoracic Oncology Group and the British Medical Association.
Dr Susan Cleator is a Consultant Clinical Oncologist based at Charing Cross Hospital, part of Imperial College Healthcare NHS Foundation Trust.
Dr Cleator trained at Oxford University and Hospitals, and undertook her oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this period she also spent three years working full-time on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. This focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy. She has published on this and a number of other aspects of oncology.
She works closely with her surgical colleagues at St Mary's hospital where she is responsible for the chemotherapy and radiotherapy aspects of their treatment, specializing in breast, colorectal and lymphomatous cancers.
Dr Cleator was previously a member of Breast Cancer Studies Group (overseeing Breast Cancer National Research portfolio) and is a member of the American Association Cancer Physicians and the British Medical Association.
Mr Stuart Wilson is a Consultant in Plastic Surgery based at The University Hospital South Manchester.
Mr Wilson qualified at Sheffield University Medical School and trained in Plastic Surgery in Leeds and Manchester. He undertook a travelling fellowship during 1998 where he spent time in the plastic and hand surgery units at Ljubljana in Slovenia, Zurich, Switzerland and Nancy in France.
He later underwent subspecialty fellowships training in Manchester for breast and hand surgery. Mr Wilson carries out a wide range of cosmetic procedures at The Alexandra Hospital including abdominal reduction, liposuction, breast enlargement and reduction, rhinoplasty (nasal surgery), face lift and eyelid surgery as well as thigh and arm lift surgery.
Professor Steve Schey is a Professor of Haematology based at King's College Hospital in London.
Prof Schey qualified at St George's Hospital in 1974, and later travelled to Australia where he worked at the Institute of Clinical Pathology and Medical Research in Sydney as Clinical Lecturer in Haematology.
He returned to London where he was the Bone Marrow Transplant Co-ordinator at the Royal Free Hospital and then the Royal Marsden. Later he moved to the Middlesex Hospital and subsequently served as Director of Clinical Haematology for the Guy's/St Thomas' Trust from 1993-2004 before moving to King’s College Hospital in 2005.
Professor Steve Schey was Secretary and then Chair of the UK Myeloma Forum 1999-2009. He has been Clinical Lead for South East Thames Cancer Network, since 2005. In addition, he is amember of the National Cancer Research Institute (NCRI) Haemoncology Cancer Steering Group, the NCRI Industry Adoption Panel and Chairman of the NCRI Myeloma Clinical Trials Committee.
Dr Steve Harland is a Consultant Medical Oncologist based at University College London Hospitals NHS Foundation Trust.
Dr Harland trained in medical oncology at the Royal Marsden Hospital following 3 years of research on clinical pharmacology (Hammersmith Hospital) and biochemical pharmacology (Institute of Cancer Research, Sutton). His MD thesis was on mechanisms of resistance to chemotherapy in human tumours. He worked as a senior lecturer in medical oncology for a year in Glasgow before being appointed to the Institute of Urology, UCL
Dr Harland was appointed Senior Lecturer in Medical Oncology at the Institute of Urology in 1986. Since then he has specialised in testis, bladder and prostate cancers and has led on the medical oncological treatment of these tumours at Middlesex and University College Hospitals.
He has served as Chairman of the MRC Bladder Cancer Group, of the North London Urology Tumour Board and he continues to chair the Castration-resistant Subgroup of the National Cancer Research Network Prostate Cancer Clinical Studies Group. He was on the Editorial Committee of the Government’s document for improving outcomes in urological cancer. He frequently speaks at International meetings.
Professor Stephen Mackinnon is a Professor of Haematology based at University College London.
Prof Mackinnon leads the bone marrow and stem cell program at UCL. He attended medical school at the University of Glasgow. He subsequently trained in Internal Medicine and Haemato-oncology in Glasgow. This was followed by a transplant fellowship at the Hammersmith Hospital in London where he developed an interest in graft-versus-leukaemia reactions. In 1990 he moved to Memorial Sloan Kettering Cancer Center in New York to continue this work in both the clinic and the lab. He made the use of donor lymphocytes less toxic by limiting the T cell dose administered to transplant recipients allowing separation of graft-versus-leukaemia responses from graft-versus-host disease.
In 1995 he returned to University College London to his current position. He became the Clinical and Academic Head of Department at the Royal Free Campus in 2004 and has recruited a highly effective and productive group of clinical and laboratory haematologists. He is an expert in the treatment of leukaemia, lymphoma, myeloma and in the use of bone marrow and stem cell transplantation to promote long-term cure of haematological malignancies. Current research interests include adoptive immunotherapy and immune reconstitution following allogeneic stem cell transplantation.
Stephen is a keen golfer whose desire to have a single figure handicap has been thwarted partly by his career choices, but primarily by a lack of real talent.
Mr Stephen Fenwick is a Consultant Hepatobiliary and General Surgeon based at the Sefton Suite Hospital and Aintree University Hospital in Liverpool.
Mr Fenwick qualified from Nottingham University and subsequently trained in Nottingham, Derby and Leeds, including a period of research for a Doctor of Medicine thesis, focusing on new treatments for patients with cancers which spread from the bowel to the liver.
Mr Fenwick was appointed as a Consultant Surgeon in 2008. He is also an Honorary Senior Lecturer at the University of Liverpool. He is currently the Clinical Lead of the Liverpool Hepatobiliary Unit, and also the Lead Cancer Clinician within the Hospital. A key development which Mr Fenwick has introduced has been the Advanced Colorectal Cancer Multidisciplinary Team Meeting, bringing together experts to ensure all patients with this condition have access to the best possible treatments.
The Liverpool Hepatobiliary Unit is one of the busiest centres in Europe for the treatment of patients with benign and malignant conditions of the liver and biliary sytem. Each year Mr Fenwick performs in excess of 100 major liver operations including laparoscopic (keyhole) liver resections, as well as around 150 laparoscopic cholecystectomies.
Mr Fenwick holds a number of external positions, including committee membership of specialist associtions, medical advisory board work for two patient charities, and as an independent Specialist Advisor for NICE.
Professor Stephen Devereux is a Consultant Haematologist based at King's College Hospital in London. He is also Professor in Lymphoma Biology at King's College London.
Professor Devereus trained in Haematology at the Royal Free and University College London Hospitals where he also worked as a Senior Lecturer.
Professor Devereux has extensive experience in the diagnosis and treatment of blood cancers with a particular interest in lymphoid malignances and chronic lymphatic leukaemia. He plays an active role in both laboratory and clinical research and directs an internationally competitive team working on the biology of lymphoma at King's College London.
Professor Devereux is Clinical Director of the London South Comprehensive Local Research Network and the South East London Cancer Research Network. He is a medical advisor to the Lymphoma Association and serves on the executive of the UK-CLL forum executive, the NCRN CLL subgroup and the Leukaemia and Lymphoma Research Fund Clinical Trials Committee.
Professor SM Lee is a Professor of Medical Oncology at UCL Cancer Institute and Cancer Research UK (CRUK) Lung Cancer Centre of Excellence, and a Consultant Oncologist at UCLH.
Prof Lee studied medicine at St Mary’s Hospital Medical School, University of London, before completing his medical oncology fellowship training at Guy’s and Christie Hospitals. He was a recipient of the American Association for Cancer Research Upjohn Award in 1993, McElwain Prize by the Association of Cancer Physicians in 1994, and completed his postgraduate PhD degree at CRUK Manchester Paterson Institute in 1994. He was appointed a Consultant Medical Oncologist at UCLH in 1998 to specialize in the treatment lung cancer and lymphoma.